Pt(0506)101

N/A

Report date: 2025/03/26 20:01:25
NME

Base Information

Drug NamePt(0506)101
Drug Alias NamePt(0506)101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis regulator BAX agonistsApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator BAXApoptosis regulator Bcl-2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Fengshuo Weikang Technology Development Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBeijing Shuobai Pharmaceutical Technology Co LtdBeijing Fengshuo Weikang Technology Development Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursStomach Neoplasms
Inactive IndicationsEsophageal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A